Last reviewed · How we verify
NCT03701438
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
trial testing Influenza Vaccine in B-cell Malignancies in 2 participants. Terminated before completion.
9 October 2019
Quick facts
| Lead sponsor | Gilead Sciences |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 2 |
| Start date | 23 October 2018 |
| Primary completion | 9 October 2019 |
| Estimated completion | 9 October 2019 |
| Sites | 2 locations across Spain, Czechia |
Drugs / interventions tested
- Influenza Vaccine — full drug profile →
Conditions studied
- B-cell Malignancies — all drugs for B-cell Malignancies →
Sponsor
Gilead Sciences — full company profile →
Who can join
18 and older, any sex, with B-cell Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03701438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Influenza Vaccine
Trials testing the same drug.
- NCT06864143 — A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in A · Phase 2 · completed
- NCT06097273 — A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age · Phase 3 · completed
- NCT05519839 — A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine · Phase 2 · completed
- NCT05074303 — Beta-glucan and Immune Response to Influenza Vaccine · Phase 2 · completed
- NCT05294588 — Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae · Phase 2 · completed
Other recruiting trials for B-cell Malignancies
Currently open trials in the same condition.
- NCT07349849 — Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies · EARLY_PHASE1 · recruiting
- NCT03125577 — Combination CAR-T Cell Therapy Targeting Hematological Malignancies · Phase 1, PHASE2 · recruiting
- NCT03050190 — A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies · Phase 1, PHASE2 · recruiting
- NCT06958679 — Evaluation of SYS6005 in Patients With Advanced Malignant Tumor · Phase 1 · recruiting
- NCT06542250 — A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R · Phase 1, PHASE2 · recruiting
Other Gilead Sciences trials
Trials by the same sponsor.
- NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
- NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
- NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
- NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
- NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03701438 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
- Last refreshed: 20 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03701438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing